Christina Capacci-Daniel is a team leader and reviewer in the FDA/OPQ Office of Process and Facilities, Division of Inspectional Assessment. She has a PhD in Organic Chemistry from Georgetown University where she studied crystallization process design and polymorphic control. As part of the early technical research and development group at Novartis Pharmaceuticals, she developed analytical methods, designed drug products for clinical trials, and worked on innovative drug delivery and manufacturing technology. Since joining the FDA in 2013, she has reviewed the manufacturing process and facilities for new and generic drug applications in addition to performing pre-approval inspections. She is also a part of the FDA Emerging Technology Team.